Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.

Diabetes Obes Metab · 2019 · PMC6585708 · PMID 30073766

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Estimates of loss of visceral fat mass showed a trend towards greater loss in the LIRA group, but the difference was not significant ( P = 0.069).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.